Bo Zheng

Dr. Bo Zheng

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2021 in International Heart Journal
Verified
Journal Article
Open access
PDF file
QQQiao Qin
Qiao Qin
BZBo Zheng
Bo Zheng
JLJiahui Liu
Jiahui Liu
BZBin Zhang
Bin Zhang
MCMing Chen
Ming Chen
YHYong Huo
Yong Huo
The side branch (SB) provisional stenting strategy is currently the recommended approach for most coronary bifurcation lesions. However, this strategy may result in SB deterioration, which is associated with an increased incidence of periprocedural myocardial infarction (PMI) and may adversely affect the long-term prognosis. Various techniques for SB protection (SB-P) have been developed to reduce SB occlusion and improve the clinical prognosis. This meta-analysis was performed to compare the outcomes of an active SB-P strategy of jailed balloon technique, balloon-stent kissing technique, and jailed Corsair technique versus the conventional SB-P strategy based on jailed wire technique.This meta-analysis included 5 studies (4 randomized and 1 observational) involving a total of 1,174 patients in whom the active and conventional SB-P strategies were compared. Fixed- and random-effects models were used to calculate summary risk ratios (RRs).The risk of SB occlusion was significantly lower in active SB-P strategy [RR 0.47, 95% confidence interval (CI) 0.30-0.73 in fixed-effect model; RR 0.52, 95% CI 0.31-0.87 in random-effect model]. The risk of PMI was similar between the two strategies (RR 0.63, 95% CI 0.30-1.33 in fixed-effect model; RR 0.71, 95%CI 0.20-2.48 in random-effect model). The rate of long-term major adverse cardiovascular events was similar between the groups (RR 0.48, 95% CI 0.15-1.48 in fixed-effect model; RR 0.49, 95% CI 0.16-1.52 in random-effect model).The active SB-P strategy in coronary bifurcation lesions is associated with reduced SB deterioration, but it does not decrease PMI or improve the long-term prognosis.

15 August 2025 in Medicine
Verified
Journal Article
Open access
TWTaotao Wang
Taotao Wang
BZBo Zheng
Bo Zheng
HYHong Yang
Hong Yang
HLHongyan Liu
Hongyan Liu
YZYun Zhou
Yun Zhou
LGLong Guo
Long Guo
Background: This meta-analysis assessed the diagnostic value of writhing and fidgety general movements (GMs) for predicting cerebral palsy. Methods: We searched PubMed, EMBASE, Cochrane Library, CINAHL, and Web of Science for cohort or case-control studies evaluating GMs. We calculated the superiority index (S), sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), and area under the curve (AUC) using STATA. Results: Eight studies were included. For writhing movements, S = 1, sensitivity = 0.99, specificity = 0.69, AUC = 0.91, and DOR = 166. For fidgety movements, S = 3, sensitivity = 0.95, specificity = 0.87, AUC = 0.97, and DOR = 144. Subgroup analyses by study design, risk population, and sample size consistently showed better predictive performance of fidgety movements. For example, in high-risk children, AUC was 0.98 for both periods, but DOR was higher for fidgety (169 vs 302 for writhing). Across subgroups, the Superiority Index of fidgety remained stable at 3. Conclusion: Fidgety GMs have significantly greater predictive value for cerebral palsy than writhing GMs. This advantage remains consistent across study types, populations, and sample sizes.

5 May 2023 in Medicine
Verified
Journal Article
Open access
BZBo Zheng
Bo Zheng
PCPingping Bm Cai
Pingping Bm Cai
YCYangjun Bm Chen
Yangjun Bm Chen
YWYuechao Bm Wu
Yuechao Bm Wu
HLHongyan Bm Liu
Hongyan Bm Liu
Background: This study evaluated the association between peptidyl arginine deiminase type IV (PADI4) and interleukin 33 (IL-33) with systemic lupus erythematosus (SLE) and juvenile idiopathic arthritis (JIA). Method: We searched the PubMed, Web of Science, Embase and Cochrane Library databases to retrieve articles published up to January 20, 2023. Stata/SE 17.0 (College Station, TX) software was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). The cohort study, case-control study focusing on the PADI4, IL-33 polymorphism, and SLE, JIA were retrieved. The data included basic information of each study and the genotypes and allele frequencies. Results: Studies in PADI4 rs2240340 = 2 and 3 IL-33(rs1891385 = 3, rs10975498 = 2, rs1929992 = 4) were found in 6 articles. Overall, only the IL-33 rs1891385 show significant association between SLE in all 5 models. The results were OR (95% CI) = 1.528 (1.312, 1.778), P = .000 in Allele model (C vs A), OR (95% CI) =1.473 (1.092, 1.988), P = .000 in Dominant model (CC + CA vs AA), 2.302 (1.583, 3.349), P = .000 in Recessive model (CC vs CA + AA), 2.711 (1.845, 3.983), P = .000 in Homozygote model (CC vs AA), 5.568 (3.943, 7.863), P = .000 in Heterozygote model (CA vs AA). PADI4 rs2240340, IL-33 rs10975498, IL-33 rs1929992 were not found to be association with the risk of SLE and JIA. In gene model, statistically significant association was found between IL-33 rs1891385 and SLE in sensitivity analysis. Egger’s publication bias plot showed there was no publication bias (P = .165). Only in recessive model the heterogeneity test was significant (I 2 = 57.9%, P ≤ .093) of IL-33 rs1891385. Conclusion: The current study suggests that in all 5 model, IL-33 rs1891385 polymorphism may be associated with genetic susceptibility to SLE. There was unclear association found between PADI4 rs2240340, IL-33 rs10975498, and IL-33 rs1929992 polymorphisms and SLE and JIA. Due to the limitations of included studies and the risk of heterogeneity, additional research is required to confirm our findings. PROSPERO registration number: CRD42023391268.

25 November 2022 in Medicine
Verified
Journal Article
Open access
BZBo Zheng
Bo Zheng
FWFang Fang Bm Wu
Fang Fang Bm Wu
XLXiao Xiao Bm Li
Xiao Xiao Bm Li
RSRen Mm Shen
Ren Mm Shen
ZZZong Mm Zheng
Zong Mm Zheng
HLHong Yan Bm Liu
Hong Yan Bm Liu
Background: This study aimed to assess the diagnostic accuracy of polymerase-chain-reaction by saliva. Method: We searched Pubmed, EMBASE, Cochrane Library and Web of Science. A case–control or cohort study designed to explore the saliva specimens for diagnosing the cytomegalovirus infection was eligible for this study. Sensitivity (SEN), specificity (SPE), diagnostic odds ratio (DOR), and summary receiver operating characteristic curves were calculated. Results: Nine articles were selected for the meta-analysis. For assessing saliva PCR with urine culture, the SEN, SPE, and DOR were 0.97 [95% confidential interval (CI):0.61,1.00] 1.00 [95%CI:0.99, 1.00] 15672 [95%CI:558, 440325], respectively; for assessing saliva PCR with urine PCR, the SEN, SPE, and DOR were 0.87 [95%CI:0.79, 0.92] 1.00 [95%CI:1.00, 1.00] 15637 [95%CI:5946, 41126], respectively; for total assessment, the SEN, SPE, and DOR were0.91 [95%CI:0.70, 0.98] 1.00 [95%CI:1.00, 1.00] 8493 [95%CI:1429, 50487], respectively. Conclusion: We reported that saliva PCR performed well in the diagnosis of cytomegalovirus infection.

23 January 2023 in Research Square
Verified
Preprint
Open access
PDF file
BZBo Zheng
Bo Zheng
CZChunli Zhang
Chunli Zhang
XZXixi Zhang
Xixi Zhang
XCXiabing Chen
Xiabing Chen
DZDifei Zhang
Difei Zhang
Background: This meta-analysis evaluated the association of sweet taste 1 receptor 2 (TAS1R2) and glucose transporter 2 (GLUT2) polymorphisms with dental caries susceptibility in children. Methods: We searched the PubMed, Web of Science, Embase and Cochrane Library databases to retrieve articles published up to 14th December 2022. Stata/SE 17.0 (TX 77845 USA) software was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). The cohort study, case-control study focusing on the TAS1R2 and GLUT2 polymorphism and dental caries in children were retrieved. The data included basic information of each study and the genotypes and allele frequencies. Results: Three studies were finally included, including 233 cases and 319 controls for rs35874116 in TAS1R2, 268 cases and 183 controls for rs5400 in GLUT2. Allelic model, homozygote model, recessive model, dominant model, and heterozygous model were established to assess the relationship between these two polymorphisms and dental caries susceptibility in children. The GLUT2 rs5400 was associated with caries in Allelic model (A vs. G), Recessive model (AA vs. AG+GG) and Homozygote model (AA vs.GG). The TAS1R2 rs35874116 was associated with caries in Dominant model (CC+CT vs. TT). The outcome from GLUT2 rs5400 and TAS1R2 rs35874116 were not stable in the sensitivity analysis. Conclusions: The results of this meta-analysis showed that the Allelic model, Recessive model and Homozygote model of the GLUT2 rs5400 and the Dominant model of TAS1R2 rs35874116 were associated with an increased risk of caries in the case group compared with the control group. But the outcome from TAS1R2 rs35874116 was not stable. PROSPERO registration number: CRD42022379301

23 November 2025 in JMIR Preprints
Verified
Preprint
Open access
LLLiyan Lin
Liyan Lin
SPSensen Pan
Sensen Pan
BZBo Zheng
Bo Zheng
FZFeifei Zhang
Feifei Zhang
BACKGROUND Cognitive frailty—typically described as the co-occurrence of physical frailty and mild cognitive impairment in the absence of dementia—has increasingly been viewed as a potentially reversible geriatric condition. It is closely tied to functional decline, disability, and later development of dementia. Although conventional motor–cognitive or physical training programs can offer benefits, they often struggle with poor engagement and limited relevance to daily life. In recent years, immersive virtual reality (VR) systems have emerged as a promising approach because they provide interactive environments that may stimulate both cognitive and motor processes in ways traditional programs cannot. Several trials have begun to test VR in older adults with cognitive frailty, but the overall effect remains uncertain, and existing reviews have generally been broad, including mixed populations or non-immersive VR. A focused evaluation of immersive motor–cognitive VR specifically in individuals diagnosed with cognitive frailty is still lacking. OBJECTIVE To determine whether immersive motor–cognitive VR training improves cognitive performance and physical frailty among adults with cognitive frailty. METHODS We searched five major databases through January 11, 2026, for randomized controlled trials involving immersive or semi-immersive VR motor–cognitive interventions in adults diagnosed with cognitive frailty. The primary outcome was global cognitive function; physical frailty was examined as a secondary outcome. Random-effects meta-analyses were conducted using standardized mean differences (SMDs) or mean differences (MDs) with 95% confidence intervals, applying the Hartung–Knapp–Sidik–Jonkman method with restricted maximum likelihood estimation.Risk of bias was evaluated using Cochrane criteria, and certainty of evidence was graded using GRADE. RESULTS Three randomized controlled trials were included. For global cognitive function, immersive motor–cognitive VR showed a small-to-moderate pooled effect favoring VR compared with non-VR control (Hedges’ g = 0.41, 95% CI −0.04 to 0.87; τ² = 0.01; I² = 14%), although the confidence interval crossed the null. For physical frailty (Fried Frailty Phenotype), two trials (n = 278) contributed data; the pooled effect was small and imprecise (Hedges’ g = −0.27, 95% CI −1.21 to 0.67; τ² = 0.00; I² = 0%). All analyses used random-effects models with REML and Hartung–Knapp adjustment, reflecting uncertainty due to the small evidence base and the limited number of trials. CONCLUSIONS Immersive motor–cognitive VR may improve global cognitive function in older adults with cognitive frailty, while effects on physical frailty–related outcomes remain uncertain. Overall estimates tended to favor VR, but certainty is limited by few trials and imprecision. Larger, methodologically robust RCTs with longer follow-up are needed. CLINICALTRIAL This study is a systematic review and meta-analysis and therefore was not prospectively registered as a clinical trial.